Nov 3, 9:10 AM ET
Indivior's 8-K says a special dividend declared by the board on September 16, 2026 triggered an increase in the conversion rate on its 0.625% Convertible Senior Notes due 2031, from 24.0033 to 30.9355 common shares per $1,000 principal, a conversion price of approximately $32.33 per share. The filing is signed by Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.), and it states that no bondholders converted their notes for common stock.
- Special dividend declared by the board on September 16, 2026 triggered the adjustment.
- Conversion rate per $1,000 principal increased from 24.0033 to 30.9355 common shares.
- Implied conversion price is approximately $32.33 per share.
- No bondholders converted their notes for common stock.
Read the filing on SEC.gov ↗
Nov 2, 9:27 AM ET
Indivior and Supernus Pharmaceuticals completed their merger on November 2, 2026, forming a combined central nervous system biopharmaceutical company operating as Supernus, Inc. Legacy Indivior stockholders own approximately 56.5% of the combined company, and former Supernus stockholders own about 43.5%. The combined entity entered into a $650 million senior secured term loan facility to help fund a $1.0 billion aggregate special cash dividend to Indivior stockholders.
- The merger was completed on November 2, 2026, creating a combined company that will trade under the ticker symbol SUPN starting November 3, 2026.
- The combined company entered into a $650 million senior secured term loan facility with Citibank, N.A. on November 2, 2026.
- Legacy Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.
- Jack Khattar serves as President and CEO, and Tony Kingsley serves as Board Chair of the combined company.
Read the filing on SEC.gov ↗
Oct 29, 7:00 AM ET
Indivior reported third-quarter 2026 results with total net revenue of $356 million, up 13% year over year, and GAAP net income of $137 million ($1.12 diluted EPS), compared with $42 million a year earlier. The company said it is on track for its previously communicated 2026 guidance as a standalone company, but that guidance will no longer apply if its merger with Supernus closes as expected on November 2, 2026.
- Total SUBLOCADE net revenue was $267 million, up 22% year over year; U.S. SUBLOCADE net revenue rose 24% to $252 million.
- Adjusted EBITDA was $211 million, up 76% from $120 million a year earlier; GAAP operating expenses fell 33% to $125 million.
- Cash and investments totaled $332 million at September 30, 2026.
- Merger with Supernus is expected to close November 2, 2026; the combined company is to trade as SUPN from November 3, 2026.
Read the filing on SEC.gov ↗
Aug 3, 6:50 AM ET
Indivior reported second-quarter 2026 total net revenue of $343 million, up 14% year over year, and GAAP net income of $122 million, compared with $18 million a year earlier, and raised its full-year 2026 guidance. The company also announced a definitive agreement for an all-stock merger of equals with Supernus Pharmaceuticals, which it expects to close in the fourth quarter, so shareholders face both the improved outlook and the pending deal's terms and risks.
- Q2 2026 total net revenue was $343 million, up from $302 million; total SUBLOCADE net revenue was $253 million, up 21%.
- GAAP net income was $122 million ($0.98 diluted EPS) versus $18 million ($0.14 diluted EPS) in Q2 2025.
- Full-year 2026 adjusted EBITDA guidance was raised to $700 million to $740 million from $620 million to $660 million; net revenue guidance was raised to $1,295 million to $1,365 million from $1,215 million to $1,285 million.
- In Q2 2026 the company repurchased 4,664,540 shares for $175 million; the Supernus merger is expected to close in the fourth quarter.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.